Lymph

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, PET, Blood pressure, Diarrhea, Doctor of Philosophy, Recurrence, Exhibit, Risk, University, SNMMI, FDA, Lymph, Serum, Radiation, Level, MD, ADT, Prostate cancer, PSA, Cancer, Dysgeusia, MedStar Georgetown University Hospital, F 18, Anaphylaxis, Antiandrogen, Medical imaging

Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
  • The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
  • Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research.
  • A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence.

Ground-breaking pilot project poised to transform breast cancer surgery in Alberta

Retrieved on: 
måndag, maj 27, 2024
Patient, Investment, News, Risk, Lymph, Breast cancer, Neoplasm, Injection, Woman, Breast, Pain, Medical imaging

Calgary, Alberta, Canada, May 27, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation and Alberta Cancer Foundation announce $5.7M toward an innovative breast cancer surgery pilot project.

Key Points: 
  • Calgary, Alberta, Canada, May 27, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation and Alberta Cancer Foundation announce $5.7M toward an innovative breast cancer surgery pilot project.
  • The Sentimag Project, made possible through the support of Calgary Health Foundation donors and a significant gift from Alberta Cancer Foundation, and because of the determination of one Calgary-based oncologist, is poised to revolutionize the way Albertans experience breast-preserving cancer surgery.
  • “We are proud to be funding the Sentimag Project with the support of our donors and Alberta Cancer Foundation.
  • This project truly aligns with the Foundation’s commitment to transforming cancer treatment and ensuring the best possible care for Albertans facing cancer.” Barbara Munroe, Board Vice Chair, Alberta Cancer Foundation.

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Patient, Agenus, Inc., Colorectal cancer, Lymph, Disease, Cancer, Peritoneum, BAL, ASCO, CRC, Brain, Society, NLM, Immunotherapy, Annual general meeting, MSS

The analysis shows that BOT/BAL is active in metastatic sites beyond the lungs and lymph nodes, including the peritoneum, soft tissue, and brain, which have historically been unresponsive to treatment.

Key Points: 
  • The analysis shows that BOT/BAL is active in metastatic sites beyond the lungs and lymph nodes, including the peritoneum, soft tissue, and brain, which have historically been unresponsive to treatment.
  • “Seeing broad activity beyond the lungs and lymph nodes is rare for immunotherapy in MSS mCRC, making BOT/BAL stand out from other treatments.
  • Patients were heavily pre-treated, with a median of four prior lines of therapy, including 21% who received prior PD-(L)1/CTLA-4 therapy.
  • Abstract Title: Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.

Parallel Bio Launches Clinical Trial in a Dish to Speed Drug Discovery

Retrieved on: 
torsdag, maj 16, 2024
Software, Research, Pharmaceutical, Robotics, Data Management, Technology, Genetics, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, 3D, Patient, Biology, Human, Laboratory, Clinical trial, Immune system, Organoid, FDA, Disease, Lymph, Safety, Drug development, AI, Animal, Drug discovery, Medicine, Cell, Pharmaceutical industry

Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.

Key Points: 
  • Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.
  • Clinical Trial in a Dish creates human models using immune organoids scaled with robotics to represent the biology and diversity of a population.
  • Clinical Trial in a Dish is Parallel Bio’s first commercially available application of its immune system platform, which utilizes lymph-node organoids at scale to replicate the human immune system across diverse populations.
  • Parallel Bio is actively signing on additional pharmaceutical partners for Clinical Trial in a Dish.

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Retrieved on: 
fredag, maj 10, 2024
Patient, SOC, CTCAE, Magnetic resonance imaging, Tumor microenvironment, FDA, MRI, Therapy, Lymph, Necrosis, Neoplasm, PCR, Research, Cancer, Intensity, Mortality, NCI, TNBC, Standard of care, Aggression, European, National Cancer Institute, Pharmaceutical industry

The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.

Key Points: 
  • The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.
  • SAKK shall undertake the trial as the "Legal Sponsor" of the study, with the regulatory agencies in Switzerland and the European Union as described in the study protocol.
  • SAKK will also ensure that all investigators and personnel who participate in the study are informed and trained.
  • Intensity shall fund the study, provide the investigational drug product, and other necessary information to conduct the trial.

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, Annual general meeting, Therapy, Port, Somnolence, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • Our proprietary Glyph™ platform allows SPT-300 to be absorbed like a dietary fat through the intestinal lymphatic system and transported into circulation.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
torsdag, maj 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

Project Lyme Harnesses the Power of Public Service Announcements to Inform Parents Their Child's Complex Illness Could Be Lyme

Retrieved on: 
onsdag, maj 8, 2024
Myalgia, Risk, CDC, Health, Arthralgia, DSM-IV codes, Parent, Depression, Conditional sentence, Tic disorder, Pressure, Patient, Lyme disease, Headache, Fatigue, Irritability, Lymph, Multimedia, Diagnosis, Infection, Fever, Anxiety, Approximation error, PSAS, Tick-borne disease, Deficit spending, Heart failure, Pharmaceutical industry

NEW YORK, May 8, 2024 /PRNewswire/ -- The CDC now estimates nearly half a million people will contract Lyme disease in the United States each year. However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients. The range of symptoms is expansive and often overwhelming, from flu-like symptoms such as fatigue, fever, enlarged lymph nodes, headaches, muscle aches, and joint pain in the early stages to more serious issues such as cognitive impairment, sleep problems, mood changes, shortness of breath or heart failure when a diagnosis is missed or delayed. Lyme has been reported in all 50 states, with case counts increasing throughout the country. As the risk of contracting a tick-borne infection increases nationally, it is imperative to educate a broader audience, especially parents of young children.

Key Points: 
  • However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients.
  • Children are at the greatest risk of contracting Lyme disease and delayed diagnosis can prevent them from living a normal life.
  • In their new PSAs , Project Lyme tells the stories of Rylyn and Pippa , two young children who are recovering from Lyme disease.
  • Project Lyme's PSAs provide advice that if you are unsure of the source of your child's illness, it could be Lyme.

Hopewell Therapeutics to Present Data Highlighting Novel Tissue Targeting Lipid Nanoparticles at the American Society of Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
tisdag, maj 7, 2024
FDA, Biting, Cell, Tissue, Trachea, LNP, GM-CSF, Hepatocellular carcinoma, Spleen, Disease, Pulmonary alveolar proteinosis, Patient, Liver, Gene, Society, Macrophage, Lymph, Lung, Infection, Messenger, PAP, Biomarker, B cell, Annual general meeting, Therapy, Gastric lavage, Vaccine

Hopewell has advanced product candidates that combine tissue-targeting LNPs with proprietary mRNA encoding for therapeutic proteins to treat rare and common diseases.

Key Points: 
  • Hopewell has advanced product candidates that combine tissue-targeting LNPs with proprietary mRNA encoding for therapeutic proteins to treat rare and common diseases.
  • These immune targeting LNPs have been successfully deployed in preclinical cancer vaccine and infectious disease vaccine models.
  • "This is an exciting time for Hopewell," shared Louis Brenner, M.D., Hopewell's President and CEO.
  • Our team is presenting data this week that showcase the progress of our ttLNPs and potential therapeutic applications that could be pursued for patient benefit."

Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series

Retrieved on: 
tisdag, april 30, 2024
Small RNA, Plasmid, Cell, LNP, Spleen, CDMO, Cytoplasm, Liver, Lymph, Toxicity, Ionization, Messenger, Lipid, Dicarboxylic acid

and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.

Key Points: 
  • and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
  • NOF CORPORATION's COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA, siRNA, and pDNA.
  • "This integrated approach, combining lipid chemistries with state-of-the-art development and manufacturing processes provides a well characterized platform for customers developing LNP-based therapies."
  • With this collaboration NOF and Phosphorex create a highly specialized LNP-focused CDMO with unique capabilities," said Yuji Yamamoto, General Manager of Life Science division of NOF CORPORATION.